

Affibody Signs Letter of Intent with SHINE Technologies for Supply of Lutetium-177

Stockholm, Sweden, February 19, 2026. Affibody AB ("Affibody") today announced that a Letter of Intent (LOI) has been signed with SHINE Technologies, LCC ("SHINE") as an additional supplier of non-carrier-added Lutetium-177 (n.c.a. Lu-177).

Under the LOI, SHINE will supply high quality n.c.a. Lu-177 to Affibody to support clinical research and development activities. This includes Affibody's lead program ABY-271, a Lu-177-conjugated, HER2-targeted Affibody[®] molecule currently under evaluation in a Phase 1 study in metastatic breast cancer, as well as additional Radioligand Therapy programs derived from Affibody's proprietary technology platform.

In addition, the parties may explore an option to extend this arrangement to include commercial Lu-177 supply for ABY-271, should the program successfully progress to commercialization.

"The Letter of Intent with SHINE represents an important step in strengthening the supply chain for our Radioligand Therapy projects," said David Beijker, CEO of Affibody. "Reliable access to high-quality Lu-177 is essential as we advance ABY-271 through clinical development and continue to expand our Radioligand Therapy pipeline."

About Affibody

Affibody is a clinical stage radiopharmaceutical company developing next generation Radioligand Therapies (RLTs) designed to deliver highly selective tumor targeting across a wide range of cancers. Leveraging decades of innovation in Affibody[®] molecule discovery and engineering, together with deep understanding of the RLT field, the company is advancing a novel pipeline focused on oncology indications with high unmet medical need. Affibody's lead RLT candidate, ABY-271, is currently being evaluated in a first-in-human clinical study in HER2 positive metastatic breast cancer.

The Affibody[®] platform has also demonstrated clinical value in immunology and inflammation, with multiple programs being advanced through strategic partnerships.

Affibody's main shareholder Patricia Industries is a part of Investor AB.

Further information can be found at: www.affibody.com.

About SHINE

Headquartered in Janesville, Wisconsin, SHINE is an industry leader in next-generation fusion, developing innovative fusion-based technology that combines safety, cost-efficiency and environmental responsibility.

SHINE has successfully commercialized fusion across multiple applications, including neutron testing markets such as neutron radiography, radiation-effects testing and fusion material research. It has commercialized and is scaling its proprietary medical isotope production processes, supplying high-quality radioisotopes essential for procedures including diagnosing heart disease and cancer as well as cancer therapy.

Beyond these applications, SHINE is pioneering nuclear waste recycling to make nuclear energy more sustainable. Its long-term purpose is to change the way humans make energy by commercializing fusion energy. Unlike other fusion companies, SHINE takes a commercially driven path mirroring successful deep-tech industries. Through this visionary approach, SHINE is advancing technology, healthcare, and sustainable energy, making a lasting impact across multiple sectors.

Learn more at www.shinefusion.com

Disclaimer

This press release contains forward-looking statements. While Affibody consider the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by several hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.

Contacts (Affibody)

David Bejker, CEO, +46 706 454 948
Peter Zerhouni, CFO and CBO, +46 706 420 044

Contacts (Media)

Richard Hayhurst, 59° North Communications, richard.hayhurst@59north.bio, +44 (0) 7711 8215727

Attachments

[Affibody Signs Letter of Intent with SHINE Technologies for Supply of Lutetium-177](#)